Clear All
716 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
Q2043 Sipuleucel-T Provenge 1 dose = minimum of 50 million autologous cd54+ cells activated with pap-gm-csf Immunotherapy Immunomodulator Prostatic Acid Phosphatase No 2010 Jul 1, 2011 In Use
NA Sorafenib Nexavar 200 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FGF, PDGFR,KIT,RET, CRAF, BRAF Yes 2005 In Use
NA Sotorasib Lumakras Multiple Chemotherapy RAS Inhibitor KRASG12C Yes 2021 In Use
J9320 Streptozocin Zanosar 1 g Chemotherapy Alkylating Agent Nitrosourea No 1982 Jan 1, 1986 In Use
NA Sunitinib malate Sutent 25 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR,KIT, RET, CSF Yes 2006 In Use
NA Sunitinib malate Sutent 37.5 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR,KIT, RET, CSF Yes 2006 In Use
NA Sunitinib malate Sutent 50 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR,KIT, RET, CSF Yes 2006 In Use
NA Sunitinib malate Sutent 12.5 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR,KIT, RET, CSF Yes 2006 In Use
J9349 Tafasitamab-cxix MONJUVI 2mg Immunotherapy Monoclonal Antibody CD19 No 2020 Apr 1, 2021 In Use
J9269 Tagraxofusp-erzs Elzonris 10mcg Immunotherapy Recombinant Fusion Protein IL3/CD123 No 2018 Oct 1, 2019 In Use
NA Talazoparib Talzenna 0.25mg, 1mg Chemotherapy Enzyme Inhibitor PARP Yes 2018 In Use
J9325 Talimogene Laherparepvec Imlygic 1 million plaque forming unites (PFU) Immunotherapy Therapeutic Cancer Vaccine Oncolytic Virus No 2015 Jan 1, 2017 In Use
C9472 Talimogene Laherparepvec Imlygic 1 million plaque forming unites (PFU) Immunotherapy Therapeutic Cancer Vaccine Oncolytic Virus No 2015 Apr 1, 2016 In Use
S0187 Tamoxifen Citrate Nolvadex, Nolvadex-D, Soltamox 10 mg Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Yes 1977 Jan 1, 2002 In Use
J1447 Tbo-filgrastim Granix 1 mcg Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor No 2015 Jan 1, 2016 In Use
J9274 Tebentafusp-tebn Kimmtrak 1mcg Immunotherapy T Cell Receptor (TCR) HLA-A*02:01 No 2022 Sep 27, 2022 In Use
J9380 Teclistamab cqyv Tecvayli 0.5mg Immunotherapy Monoclonal Antibody BCMA, CD3 No 2022 Jul 11, 2023 In Use
J9328 Temozolomide Temodar 1 mg Chemotherapy Alkylating Agent Tetrazine No 1999 Jan 1, 2010 In Use
J8700 Temozolomide Temodar 5 mg Chemotherapy Alkylating Agent Tetrazine Yes 1999 Jan 1, 2001 In Use
C1086 Temozolomide Temodar 5 mg Chemotherapy Alkylating Agent Tetrazine Yes 1999 Jan 1, 2010 In Use
C9253 Temozolomide Temodar 1 mg Chemotherapy Alkylating Agent Tetrazine No 1999 Jan 1, 2010 In Use
J9330 Temsirolimus Torisel 1 mg Chemotherapy Enzyme Inhibitor mTOR No 2007 Jan 1, 2009 In Use
Q2017 Teniposide Teniposide 50 mg Chemotherapy Plant Alkaloid Epipodophyllotoxins No 1992 Jul 1, 2000 In Use
NA Tepotinib Hydrochloride Tepmetko 225mg Chemotherapy Tyrosine Kinase Inhibitor MET Yes 2021 In Use
J3121 Testosterone Enanthate Testosterone Enanthate 1 mg Hormonal Therapy Androgen No 1953 Jan 1, 2015 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.